Update on Statin Treatment in Patients with Neuropsychiatric Disorders

Overview

Journal Life (Basel)

Specialty Biology

Date 2021 Dec 24

PMID 34947895

Citations 13

Authors

Razieh Avan

Adeleh Sahebnasagh

Javad Hashemi

Mahila Monajati

Fatemeh Faramarzi

Neil C Henney

Fabrizio Montecucco

Tannaz Jamialahmadi

Amirhossein Sahebkar

Affiliations

Soon will be listed here.

Abstract

Statins are widely accepted as first-choice agents for the prevention of lipid-related cardiovascular diseases. These drugs have both anti-inflammatory and anti-oxidant properties, which may also make them effective as potential treatment marked by perturbations in these pathways, such as some neuropsychiatric disorders. In this narrative review, we have investigated the effects of statin therapy in individuals suffering from major depressive disorder (MDD), schizophrenia, anxiety, obsessive-compulsive disorder (OCD), bipolar disorder (BD), delirium, and autism spectrum disorders using a broad online search of electronic databases. We also explored the adverse effects of these drugs to obtain insights into the benefits and risks associated with their use in the treatment of these disorders. Lipophilic statins (including simvastatin) because of better brain penetrance may have greater protective effects against MDD and schizophrenia. The significant positive effects of statins in the treatment of anxiety disorders without any serious adverse side effects were shown in numerous studies. In OCD, BD, and delirium, limitations, and contradictions in the available data make it difficult to draw conclusions on any positive effect of statins. The positive effects of simvastatin in autism disorders have been evaluated in only a small number of clinical trials. Although some studies showed positive effect of statins in some neuropsychiatric disorders, further prospective studies are needed to confirm this and define the most effective doses and treatment durations.

Citing Articles

Proteomic Profiling Reveals Age-Related Changes in Transporter Proteins in the Human Blood-Brain Barrier.

Zhou X, Azimi M, Handin N, Riselli A, Vora B, Chun E bioRxiv. 2024; .

PMID: 39091855 PMC: 11291171. DOI: 10.1101/2024.07.26.604313.

Is cholesterol both the lock and key to abnormal transmembrane signals in Autism Spectrum Disorder?.

Lingwood C Lipids Health Dis. 2024; 23(1):114.

PMID: 38643132 PMC: 11032007. DOI: 10.1186/s12944-024-02075-3.

Statin for mood and inflammation among adult patients with major depressive disorder: an updated meta-analysis.

Xiao X, Deng H, Li P, Sun J, Tian J Front Psychiatry. 2023; 14:1203444.

PMID: 38034928 PMC: 10684957. DOI: 10.3389/fpsyt.2023.1203444.

The pharmacological bases for repurposing statins in depression: a review of mechanistic studies.

De Giorgi R, Rizzo Pesci N, Rosso G, Maina G, Cowen P, Harmer C Transl Psychiatry. 2023; 13(1):253.

PMID: 37438361 PMC: 10338465. DOI: 10.1038/s41398-023-02533-z.

Atorvastatin Improves the Propionic Acid-Induced Autism in Rats: The Roles of Sphingosine-1-Phosphate and Anti-inflammatory Action.

Durankus F, Budak K, Albayrak Y, Sever I, Ozkul B, Uyanikgil Y Cureus. 2023; 15(3):e36870.

PMID: 37123681 PMC: 10147056. DOI: 10.7759/cureus.36870.

References

Redlich C, Berk M, Williams L, Sundquist J, Sundquist K, Li X . Statin use and risk of depression: a Swedish national cohort study. BMC Psychiatry. 2014; 14:348. PMC: 4266881. DOI: 10.1186/s12888-014-0348-y. View

Kim S, Bae K, Kim J, Shin I, Hong Y, Ahn Y . The use of statins for the treatment of depression in patients with acute coronary syndrome. Transl Psychiatry. 2015; 5:e620. PMC: 4564569. DOI: 10.1038/tp.2015.116. View

Zandi P, Sparks D, Khachaturian A, Tschanz J, Norton M, Steinberg M . Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry. 2005; 62(2):217-24. DOI: 10.1001/archpsyc.62.2.217. View

Rahim F, Sayyah M . Effects of atorvastatin on treatment-resistant obsessive-compulsive disorder: A double-blind randomized trial. Psychiatr Pol. 2018; 52(4):719-729. DOI: 10.12740/PP/OnlineFirst/69422. View

Lilly S, Mortensen E, Frei C, Pugh M, Mansi I . Comparison of the risk of psychological and cognitive disorders between persistent and nonpersistent statin users. Am J Cardiol. 2014; 114(7):1035-9. DOI: 10.1016/j.amjcard.2014.07.010. View

Mayer C, Gruber H, Landl E, Pailer S, Scharnagl H, Truschnig-Wilders M . Rosuvastatin reduces interleukin-6-induced expression of C-reactive protein in human hepatocytes in a STAT3- and C/EBP-dependent fashion. Int J Clin Pharmacol Ther. 2007; 45(6):319-27. DOI: 10.5414/cpp45319. View

Yang J, Hu Z . Neuroprotective effects of atorvastatin against cerebral ischemia/reperfusion injury through the inhibition of endoplasmic reticulum stress. Neural Regen Res. 2015; 10(8):1239-44. PMC: 4590235. DOI: 10.4103/1673-5374.162755. View

Raison C, Rutherford R, Woolwine B, Shuo C, Schettler P, Drake D . A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2012; 70(1):31-41. PMC: 4015348. DOI: 10.1001/2013.jamapsychiatry.4. View

Berk M, Dean O, Cotton S, Jeavons S, Tanious M, Kohlmann K . The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry. 2014; 75(6):628-36. DOI: 10.4088/JCP.13m08454. View

10.

Agostini J, Tinetti M, Han L, McAvay G, Foody J, Concato J . Effects of statin use on muscle strength, cognition, and depressive symptoms in older adults. J Am Geriatr Soc. 2007; 55(3):420-5. DOI: 10.1111/j.1532-5415.2007.01071.x. View

11.

Kamel N, Gammack J . Insomnia in the elderly: cause, approach, and treatment. Am J Med. 2006; 119(6):463-9. DOI: 10.1016/j.amjmed.2005.10.051. View

12.

Parizadeh S, Azarpazhooh M, Moohebati M, Nematy M, Ghayour-Mobarhan M, Tavallaie S . Simvastatin therapy reduces prooxidant-antioxidant balance: results of a placebo-controlled cross-over trial. Lipids. 2011; 46(4):333-40. DOI: 10.1007/s11745-010-3517-x. View

13.

Keller W, Kum L, Wehring H, Koola M, Buchanan R, Kelly D . A review of anti-inflammatory agents for symptoms of schizophrenia. J Psychopharmacol. 2012; 27(4):337-42. PMC: 3641824. DOI: 10.1177/0269881112467089. View

14.

Dean O, Maes M, Ashton M, Berk L, Kanchanatawan B, Sughondhabirom A . Protocol and rationale-the efficacy of minocycline as an adjunctive treatment for major depressive disorder: a double blind, randomised, placebo controlled trial. Clin Psychopharmacol Neurosci. 2015; 12(3):180-8. PMC: 4293162. DOI: 10.9758/cpn.2014.12.3.180. View

15.

Weitz-Schmidt G . Statins as anti-inflammatory agents. Trends Pharmacol Sci. 2002; 23(10):482-6. DOI: 10.1016/s0165-6147(02)02077-1. View

16.

Cunningham C . Systemic inflammation and delirium: important co-factors in the progression of dementia. Biochem Soc Trans. 2011; 39(4):945-53. PMC: 4157218. DOI: 10.1042/BST0390945. View

17.

ONeil A, Sanna L, Redlich C, Sanderson K, Jacka F, Williams L . The impact of statins on psychological wellbeing: a systematic review and meta-analysis. BMC Med. 2012; 10:154. PMC: 3568015. DOI: 10.1186/1741-7015-10-154. View

18.

Otte C, Zhao S, Whooley M . Statin use and risk of depression in patients with coronary heart disease: longitudinal data from the Heart and Soul Study. J Clin Psychiatry. 2012; 73(5):610-5. DOI: 10.4088/JCP.11m07038. View

19.

Abbasi S, Mohammadinejad P, Shahmansouri N, Salehiomran A, Beglar A, Zeinoddini A . Simvastatin versus atorvastatin for improving mild to moderate depression in post-coronary artery bypass graft patients: A double-blind, placebo-controlled, randomized trial. J Affect Disord. 2015; 183:149-55. DOI: 10.1016/j.jad.2015.04.049. View

20.

Ramkumar S, Raghunath A, Raghunath S . Statin Therapy: Review of Safety and Potential Side Effects. Acta Cardiol Sin. 2016; 32(6):631-639. PMC: 5126440. DOI: 10.6515/acs20160611a. View